JCP
RARE icon

Jabre Capital Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Jabre Capital Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-35,900
Closed -$1.83M – 188
2018
Q1 		$1.83M Buy
+35,900
New +$1.81M 0.39% 69

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jabre Capital Partners's RARE Position: Q2 2018 in Review

Jabre Capital Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2018, closing a stake of 35,900 shares — an estimated $1.83M sold.

Jabre Capital Partners first reported a position in RARE in Q1 2018 and held it in 1 quarter. The position peaked at $1.83M in Q1 2018. 158 funds tracked by Wall St. Rank hold RARE as of Q2 2018.

  • Jabre Capital Partners reported no remaining Ultragenyx Pharmaceutical position as of Q2 2018 after selling out during the quarter.
  • Jabre Capital Partners sold 35,900 Ultragenyx Pharmaceutical shares in Q2 2018, an estimated $1.83M.
  • Jabre Capital Partners first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and held it in 1 quarter.
  • Jabre Capital Partners's Ultragenyx Pharmaceutical position peaked at $1.83M in Q1 2018.
  • 158 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2018.

Based on Jabre Capital Partners's 13F filing for Q2 2018, filed 14 Aug 2018.